Future research will show whether downregulation or overexpression of Dyrk1a is a beneficial tool in the treatment of cardiomyopathies as excess Dyrk1a appears to be useful in preventing maladaptive remodeling due to cardiac hypertrophy. The gene discussed is DYRK1A; the disease is cardiac hypertrophy.